ReviewNanoscale advances2024
Cutting-edge approaches for targeted drug delivery in breast cancer: beyond conventional therapies.
Review in Nanoscale advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- 4D nanoimaging-guided smart therapeutics: spatiotemporal control of disease microenvironments.RSC advances · 2026Review
- Current Study of Alpha-Mangostin in Breast Cancer Therapy: Antioxidant Mechanisms and Redox Modulation from In Silico to In Vivo Studies.Antioxidants (Basel, Switzerland) · 2026Review
- Blood cell membrane camouflaged probiotic-powered micro-robot for dual-targeted thrombus therapy.Materials today. Bio · 2026Article
- Advances in improving cancer immunotherapy with nanotechnology: from smart nanoparticles to synergistic combination strategies.Molecular cancer · 2026Review
- Development of a pH-responsive starch-based nanocarrier polyacrylic acid containing SiOScientific reports · 2026Article
- From State, Pathway, to Niche: The Ternary Network of Breast Cancer Stem-like Cells Driving Tumor Progression and Combination Therapy Prospects.Biomolecules · 2026Review
- Review
- Advancements in nanobiosensors for early cancer detection, challenges, treatment, and future prospects: a comprehensive review.Discover nano · 2026Review
- Peptomer Linkers Enable Kinetic Control over Co-Delivery of Multiple Chemotherapeutics.Advanced healthcare materials · 2026Article
- In vivo and in silico approaches for evaluating nerolidol-β-cyclodextrin nanoparticles: Antioxidant potential and hormonal modulation in DMBA-induced mammary carcinoma.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Toward the rational design of oncogenic TASK-3 channel inhibitor peptides and nanoconjugate complexes.Frontiers in pharmacology · 2026Review
- Targeting cancer hallmarks with microbiome-derived bacteriocins and postbiotics: molecular mechanisms and translational opportunities in oncology.Frontiers in oncology · 2026Review
- The Potential of Next-generation Multi-functional Nanoplatforms for Breast Cancer.Anti-cancer agents in medicinal chemistry · 2026Review
- Demystifying anti-inflammatory therapeutic strategies against pancreatitis and concomitant diseases: a 2025 perspective.Theranostics · 2026Review
- The impact of early integrated palliative care on symptom burden and quality of life in patients with advanced breast cancer.Frontiers in oncology · 2026Article
- Comprehensive analysis of gene expression alterations in breast cancer patients via PKCθ-TBK1-mTORC1 signaling pathway.BMC cancer · 2025Article
- Protein Engineering and Drug Discovery: Importance, Methodologies, Challenges, and Prospects.Biomolecules · 2025Review
- Innovative theranostic potential of graphene quantum dot nanocomposites in breast cancer.Medical oncology (Northwood, London, England) · 2025Review
- Nanotechnology in oncology: advances in biosynthesis, drug delivery, and theranostics.Discover oncology · 2025Review
- From Pioneering Discoveries to Innovative Therapies: A Journey Through the History and Advancements of Nanoparticles in Breast Cancer Treatment.Breast cancer (Dove Medical Press) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is a global health challenge with staggering statistics underscoring its pervasive impact. The burden of this disease is measured in terms of its prevalence and the challenges it poses to healthcare systems, necessitating a closer look at its epidemiology and impact. Current breast cancer treatments, including surgery, chemotherapy, radiation therapy, and targeted therapies, have made significant strides in improving patient outcomes. However, they are not without limitations, often leading to adverse effects and the development of drug resistance. This comprehensive review delves into the complex landscape of breast cancer, including its incidence, current treatment modalities, and the inherent limitations of existing therapeutic approaches. It also sheds light on the promising role of nanotechnology, encompassing both inorganic and organic nanoparticles equipped with the ability to selectively deliver therapeutic agents to tumor sites, in the battle against breast cancer. The review also addresses the emerging therapies, their associated challenges, and the future prospects of targeted drug delivery in breast cancer management.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.